Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDCO-216 dose-finding trial in recent acute coronary syndrome
2014-005462-30Phase 2Terminated
- Sponsor
- The Medicines Company
- Start
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS) and coronary arteriosclerosis comparing MDCO-216 with Placebo (2 arms). Primary endpoint: Change in percent atheroma volume. Started Sep 2016; status: terminated.
02
Drugs
apolipoprotein A-I Milano
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2014-005462-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005462-30.